SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Autres langues Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Actions

1349

CNE1000000W4

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:49 06/05/2024			Varia. 5j.	Varia. 1 janv.
2,18 ^HKD	+1,40 %		+0,46 %	-14,51 %

29/04	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
01/04	Fudan-Zhangjiang Bio prévoit une baisse des bénéfices et des revenus en 2023	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	22/04
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	01/04
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	28/03
Fudan-Zhangjiang Bio's 2023 Profit Falls	26/02
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan	04/01
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products	03/01
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China	27/12
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial	18/12
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	18/12
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	13/11
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	13/11
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation	08/11
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	08/11
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	31/10/23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	27/10/23
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23/10/23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	20/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Actions

1349

CNE1000000W4

Autres langues

Filtres